Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GRNA GreenLight Biosciences	$0.30	$0.30	$0.18 ▼ $5.90	$45.43M	1.44	486,986 shs	732 shs
IKT Inhibikase Therapeutics	$1.73 +1.2%	$1.80	$1.12 ▼ $4.20	$128.61M	0.9	194,918 shs	50,321 shs
IZTC Invizyne Technologies	$10.03 +1.7%	$10.67	$8.50 ▼ $23.00	$62.73M	N/A	37,647 shs	489 shs
PLX Protalix BioTherapeutics	$1.52 -5.9%	$1.49	$0.89 ▼ $3.10	$120.61M	-0.21	846,558 shs	883,850 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GRNA GreenLight Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
IKT Inhibikase Therapeutics	-2.29%	-1.16%	-11.86%	-15.76%	+24.82%
IZTC Invizyne Technologies	+1.96%	-0.42%	+2.27%	-31.05%	+1,003,289,900.00%
PLX Protalix BioTherapeutics	-1.83%	+8.78%	+13.38%	-3.59%	+54.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	1.7212 of 5 stars	3.3	2.0	0.0	0.0	1.1	0.0	1.3
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	3.403 of 5 stars	3.5	2.0	0.0	0.0	3.4	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GRNA GreenLight Biosciences	0.00	N/A	N/A	N/A
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	275.72% Upside
IZTC Invizyne Technologies	0.00	N/A	N/A	N/A
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	890.10% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GRNA GreenLight Biosciences	$10.20M	4.45	N/A	N/A	$0.32 per share	0.94
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	$59.76M	2.02	$0.09 per share	17.80	$0.47 per share	3.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GRNA GreenLight Biosciences	-$167.05M	-$1.14	N/A	∞	N/A	-1,521.00%	-374.26%	-122.78%	N/A
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
IZTC Invizyne Technologies	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.89	N/A	-21.03%	-30.89%	-11.74%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
IZTC Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GRNA GreenLight Biosciences	0.49	1.21	1.21
IKT Inhibikase Therapeutics	N/A	0.85	0.85
IZTC Invizyne Technologies	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	1.98	1.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GRNA GreenLight Biosciences	24.41%
IKT Inhibikase Therapeutics	3.81%
IZTC Invizyne Technologies	N/A
PLX Protalix BioTherapeutics	16.53%

Insider Ownership

Company	Insider Ownership
GRNA GreenLight Biosciences	30.30%
IKT Inhibikase Therapeutics	7.30%
IZTC Invizyne Technologies	N/A
PLX Protalix BioTherapeutics	6.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GRNA GreenLight Biosciences	280	151.68 million	105.72 million	Not Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
IZTC Invizyne Technologies	29	6.25 million	N/A	N/A
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable

GRNA, IKT, PLX, and IZTC Headlines

Recent News About These Companies

Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript

4 hours ago | seekingalpha.com

Protalix BioTherapeutics lifts revenue on strong Elfabrio demand

August 14 at 8:39 AM | proactiveinvestors.com

Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results

August 14 at 7:01 AM | prnewswire.com

Protalix BioTherapeutics, Inc. (NYSE:PLX) Director Aharon Schwartz Buys 129,000 Shares

August 13 at 5:41 AM | insidertrades.com

Head-To-Head Analysis: Protalix BioTherapeutics (NYSE:PLX) & AlloVir (NASDAQ:ALVR)

August 10, 2025 | americanbankingnews.com

Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025

August 7, 2025 | prnewswire.com

Protalix Lawsuit Dismissed After Bylaws Amendment

August 1, 2025 | tipranks.com

Protalix BioTherapeutics Names Gilad Mamlok Chief Financial Officer

July 21, 2025 | marketwatch.com

Protalix BioTherapeutics Names SVP and CFO

July 21, 2025 | contractpharma.comC

Protalix Biotherapeutics Inc.: Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer

July 21, 2025 | finanznachrichten.de

Protalix BioTherapeutics welcomes new finance chief

July 21, 2025 | proactiveinvestors.com

PLX | Protalix BioTherapeutics Inc. Annual Cash Flow Statement ...

July 10, 2025 | marketwatch.com

Protalix BioTherapeutics joins Russell 3000 and 2000 indexes following annual reconstitution

June 30, 2025 | proactiveinvestors.com

Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

May 14, 2025 | finance.yahoo.com

PLX: First Quarter Results

May 13, 2025 | msn.com

Earnings call transcript: Protalix Q1 2025 results miss forecasts, stock plunges

May 10, 2025 | uk.investing.com

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript

May 10, 2025 | insidermonkey.com

Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

May 10, 2025 | finanznachrichten.de

Protalix BioTherapeutics Q1 Earnings Preview

May 10, 2025 | msn.com

1PLX : Uncovering Potential: Protalix BioTherapeutics's Earnings Preview

May 10, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRNA, IKT, PLX, and IZTC Company Descriptions

GreenLight Biosciences NASDAQ:GRNA

FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.

Inhibikase Therapeutics NYSE:IKT

$1.73 +0.02 (+1.17%)

Closing price 03:59 PM Eastern

Extended Trading

$1.72 -0.01 (-0.58%)

As of 04:07 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Invizyne Technologies NASDAQ:IZTC

$10.03 +0.17 (+1.73%)

As of 08/12/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.

Protalix BioTherapeutics NYSE:PLX

$1.52 -0.10 (-5.90%)

Closing price 03:59 PM Eastern

Extended Trading

$1.52 0.00 (0.00%)

As of 04:10 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time